SK287972B6 - Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof - Google Patents

Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof Download PDF

Info

Publication number: SK287972B6
Authority: SK; Slovakia
Prior art keywords: thrombus; embolus; diseases caused; prevention; aspirin
Prior art date: 2000-12-25

Application number

SK754-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK7542003A3 (en

Inventor

Fumitoshi Asai

Atsuhiro Sugidachi

Taketoshi Ogawa

Teruhiko Inoue

Original Assignee

Daiichi Sankyo Company Limited

Ube Industries, Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-25

Filing date

2001-12-20

Publication date

2012-08-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18858878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287972(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-20 Application filed by Daiichi Sankyo Company Limited, Ube Industries, Ltd filed Critical Daiichi Sankyo Company Limited

2003-12-02 Publication of SK7542003A3 publication Critical patent/SK7542003A3/sk

2012-08-06 Publication of SK287972B6 publication Critical patent/SK287972B6/sk

Links

BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 23
229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
150000001875 compounds Chemical class 0.000 title description 14
AEMXNRIHRLEYAK-UHFFFAOYSA-N pyridin-2-yl acetate Chemical class CC(=O)OC1=CC=CC=N1 AEMXNRIHRLEYAK-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 31
208000005189 Embolism Diseases 0.000 claims abstract description 25
208000007536 Thrombosis Diseases 0.000 claims abstract description 25
201000010099 disease Diseases 0.000 claims abstract description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
239000004480 active ingredient Substances 0.000 claims abstract description 9
DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims description 20
230000002265 prevention Effects 0.000 claims description 17
-1 α-cyclopropylcarbonyl-2-fluorobenzyl Chemical group 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 abstract description 7
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 6
210000001772 blood platelet Anatomy 0.000 abstract 1
230000000694 effects Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000000034 method Methods 0.000 description 5
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000003883 ointment base Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
229940126062 Compound A Drugs 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
235000019426 modified starch Nutrition 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
150000004760 silicates Chemical class 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
206010048631 Coronary artery dissection Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
150000001510 aspartic acids Chemical class 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
LGBHQFWRSMFRJF-UHFFFAOYSA-N butanedioic acid;oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)CCC(O)=O LGBHQFWRSMFRJF-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000010102 embolization Effects 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000004571 lime Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920002529 medical grade silicone Polymers 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SK754-2003A 2000-12-25 2001-12-20 Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof SK287972B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000392983		2000-12-25
PCT/JP2001/011201 WO2002051412A1 (en)	2000-12-25	2001-12-20	Medicinal compositions containing aspirin

Publications (2)

Publication Number	Publication Date
SK7542003A3 SK7542003A3 (en)	2003-12-02
SK287972B6 true SK287972B6 (sk)	2012-08-06

Family

ID=18858878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK754-2003A SK287972B6 (sk)	2000-12-25	2001-12-20	Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof

Country Status (25)

Country	Link
US (3)	US20040024013A1 (cs)
EP (1)	EP1350511B1 (cs)
KR (1)	KR100692934B1 (cs)
CN (1)	CN100341506C (cs)
AT (1)	ATE407675T1 (cs)
AU (1)	AU2002217464B2 (cs)
BR (1)	BR0116531A (cs)
CA (1)	CA2432644C (cs)
CY (1)	CY1108626T1 (cs)
CZ (1)	CZ297570B6 (cs)
DE (1)	DE60135780D1 (cs)
DK (1)	DK1350511T3 (cs)
ES (1)	ES2311498T3 (cs)
HU (1)	HUP0400644A3 (cs)
IL (2)	IL156456A0 (cs)
MX (1)	MXPA03005770A (cs)
NO (1)	NO20032902L (cs)
NZ (1)	NZ526540A (cs)
PL (1)	PL206138B1 (cs)
PT (1)	PT1350511E (cs)
RU (1)	RU2262933C2 (cs)
SK (1)	SK287972B6 (cs)
TW (1)	TWI293249B (cs)
WO (1)	WO2002051412A1 (cs)
ZA (1)	ZA200304878B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL208386B1 (pl) *	2000-07-06	2011-04-29	Daiichi Sankyo Company	Sole addycyjne 2-acetoksy-5-(α-cyklopropylokarbonylo-2-flurobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, lekarstwo zawierające jako składnik czynny te sole, zastosowanie soli, sposoby wytwarzania soli addycyjnych 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, sposób wytwarzania chlorowodorku 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny
PL206138B1 (pl)	2000-12-25	2010-07-30	Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited	Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
WO2004098713A2 (en) *	2003-05-05	2004-11-18	Eli Lilly And Company	Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)
CN100488163C (zh) *	2005-01-19	2009-05-13	华为技术有限公司	组播业务处理方法和系统
EP1893205A4 (en) *	2005-06-17	2010-06-30	Lilly Co Eli	DOSAGE FOR PRASUGREL
DE102005029612A1 (de) *	2005-06-23	2007-01-04	Hochschule Bremen	Vorrichtung zum Erzeugen eines Panoramabildes
WO2007024472A2 (en) *	2005-08-19	2007-03-01	Eli Lilly And Company	USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
PL2032521T3 (pl) *	2006-06-27	2010-05-31	Sandoz Ag	Nowy sposób wytwarzania soli
US20100280064A1 (en) *	2006-12-07	2010-11-04	Tomoyuki Watanabe	Pharmaceutical composition having improved storage stability
CA2672134C (en) *	2006-12-07	2015-02-10	Daiichi Sankyo Company, Limited	Solid medicinal preparation containing mannitol or lactose
TWI482641B (zh) *	2006-12-07	2015-05-01	Daiichi Sankyo Co Ltd	含有低取代度羥丙基纖維素之醫藥組成物
EP2100606A4 (en) *	2006-12-07	2009-12-30	Daiichi Sankyo Co Ltd	PREPARATION WITH FILM COVER AND IMPROVED STABILITY
CA2672157C (en) *	2006-12-07	2016-07-26	Daiichi Sankyo Company, Limited	Method for producing solid preparation
CN101675058A (zh) *	2007-03-02	2010-03-17	第一三共株式会社	用于制备高纯度普拉格雷盐酸盐的方法
US8343995B2 (en)	2007-04-27	2013-01-01	Cydex Pharmaceuticals, Inc.	Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CN101177430A (zh) *	2007-12-11	2008-05-14	鲁南制药集团股份有限公司	氢化吡啶衍生物及其盐的制备方法
US20090281136A1 (en) *	2008-05-08	2009-11-12	Sandeep Mhetre	Prasugrel pharmaceutical formulations
KR20110045034A (ko)	2008-08-02	2011-05-03	루난 파마슈티컬 그룹 코퍼레이션	프라수그렐 황산수소염 및 이의 약제학적 조성물 및 용도
CN102625658B (zh)	2009-05-13	2015-01-28	锡德克斯药物公司	包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
CN102228691A (zh) *	2011-06-29	2011-11-02	北京阜康仁生物制药科技有限公司	阿司匹林和一种抗血小板药物的药物组合物
US9757395B2 (en) *	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
CN105473133A (zh)	2013-04-30	2016-04-06	欧缇托匹克公司	干粉制剂及使用方法
CN112656780A (zh)	2014-02-20	2021-04-16	奥迪托皮克股份有限公司	用于吸入的干粉制剂
WO2016122421A1 (en)	2015-01-29	2016-08-04	Pharmactive Ilaç Sanayi Ve Ticaret A.Ş.	Stable pharmaceutical compositions containing prasugrel base

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2890240A (en) *	1956-03-28	1959-06-09	Monsanto Chemicals	Aspirin crystallisation
US3235583A (en) *	1964-07-22	1966-02-15	Norwich Pharma Co	Preparation of aspirin
US3890240A (en) *	1966-11-28	1975-06-17	Pitney Bowes Inc	Toner compositions and methods for their preparation
FR2345150A2 (fr)	1975-08-06	1977-10-21	Centre Etd Ind Pharma	Nouveaux derives de la thienopyridine, et leur application
FR2215948B1 (cs)	1973-02-01	1976-05-14	Centre Etd Ind Pharma
FR2307538A1 (fr) *	1975-04-18	1976-11-12	Centre Etd Ind Pharma	Nouveau medicament anti-agregant plaquettaire
FR2312247A1 (fr)	1975-05-30	1976-12-24	Parcor	Derives de la thieno-pyridine, leur procede de preparation et leurs applications
FR2358150A1 (fr) *	1976-07-13	1978-02-10	Parcor	Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
FR2376860A1 (fr) *	1977-01-07	1978-08-04	Parcor	Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique
GB1576511A (en) *	1977-03-29	1980-10-08	Parcor	Thieno(2,3 - c) and (3,2 - c) pyridines process for their preparation and therapeutic applications thereof
GB2038625B (en) *	1978-12-29	1983-01-12	Parcor	Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity
CA1147658A (en)	1980-01-03	1983-06-07	Edouard Panak	Therapeutic compositions having antithrombotic and anti-blood-platelet- aggregating activity
US4321266A (en) *	1980-10-06	1982-03-23	Sanofi	5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine
US4400384A (en) *	1980-10-06	1983-08-23	Sanofi, S.A.	5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof
FR2495156A1 (fr) *	1980-11-28	1982-06-04	Sanofi Sa	Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2528848A1 (fr) *	1982-06-16	1983-12-23	Sanofi Sa	Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
FR2530247B1 (fr) *	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) *	1985-01-31	1987-03-20	Sanofi Sa	Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2596392B1 (fr)	1986-03-27	1988-08-05	Sanofi Sa	Derives de l'acide a-(hydroxy-3 oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenylacetique, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2597102B1 (fr)	1986-04-14	1988-08-26	Sanofi Sa	Derives de l'acide a-(hydroxy-7 tetrahydro-4,5,6,7 thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
FR2652579B1 (fr) *	1989-10-02	1992-01-24	Sanofi Sa	Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
US5401730A (en) *	1990-07-06	1995-03-28	The Hope Heart Institute	Method for reducing platelet aggregation
ZA926784B (en) *	1991-09-09	1993-03-29	Sankyo Co	Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation.
FI101150B (fi)	1991-09-09	1998-04-30	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2087743C (en)	1992-02-06	1999-04-27	Akio Odawara	Pharmaceutical composition for inhibiting platelet aggregation
EP0573975A1 (en)	1992-06-08	1993-12-15	Fuji Photo Film Co., Ltd.	2-alkoxycarbonyl-5-o-chlorobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine derivative and process for producing the same
US5594004A (en)	1993-03-17	1997-01-14	Meiji Seika Kabushiki Kaisha	Compound with platelet aggregation inhibitor activity
JPH06271582A (ja)	1993-03-18	1994-09-27	Fuji Photo Film Co Ltd	４，５，６，７−テトラヒドロチエノ〔３，２−ｃ〕ピリジン誘導体の製造方法
WO1996011203A1 (en) *	1994-10-07	1996-04-18	Ube Industries, Ltd.	2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
JP3564791B2 (ja)	1995-04-21	2004-09-15	宇部興産株式会社	α−アミノケトン類の製造方法
FR2744918B1 (fr) *	1996-02-19	1998-05-07	Sanofi Sa	Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
WO1999065500A1 (en) *	1998-06-17	1999-12-23	Bristol-Myers Squibb Company	Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6509348B1 (en) *	1998-11-03	2003-01-21	Bristol-Myers Squibb Company	Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IT1306980B1 (it)	1999-01-13	2001-10-11	Magneti Marelli Spa	Gruppo motore-cambio di velocita', in particolare per motocicli.
CN1108798C (zh) *	1999-01-26	2003-05-21	广东药学院	一种治疗、预防血栓形成及中风的复方制剂及其制备方法
JP2000266780A (ja)	1999-03-18	2000-09-29	Matsushita Electric Ind Co Ltd	プローブカードとそれを用いた検査装置
IT1311924B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311923B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
FR2792836B3 (fr)	1999-04-30	2001-07-27	Sanofi Sa	Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
PL208386B1 (pl) *	2000-07-06	2011-04-29	Daiichi Sankyo Company	Sole addycyjne 2-acetoksy-5-(α-cyklopropylokarbonylo-2-flurobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, lekarstwo zawierające jako składnik czynny te sole, zastosowanie soli, sposoby wytwarzania soli addycyjnych 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, sposób wytwarzania chlorowodorku 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny
JP4001199B2 (ja)	2000-07-06	2007-10-31	第一三共株式会社	ヒドロピリジン誘導体酸付加塩
CA2428191A1 (en) *	2000-11-07	2002-05-30	Bristol-Myers Squibb Company	Acid derivatives useful as serine protease inhibitors
PL206138B1 (pl)	2000-12-25	2010-07-30	Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited	Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
WO2003011824A1 (en) *	2001-07-31	2003-02-13	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
DE10305984A1 (de) *	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
KR20070052780A (ko) *	2004-09-21	2007-05-22	테바 파마슈티컬 인더스트리즈 리미티드	결정질 클로피도그렐 브롬산염 및 이의 제조 방법
US20110003847A1 (en) *	2008-02-06	2011-01-06	Helm Ag	Prasugrel Salts with Improved Properties
DE202008003557U1 (de)	2008-03-13	2008-06-05	Riela - Getreidetechnik Karl-Heinz Knoop E.K.	Schubwendetrockner mit Feuchte-Messeinrichtung
ES2353853T3 (es)	2008-04-25	2011-03-07	Sandoz Ag	SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
GB2469883A (en)	2009-04-30	2010-11-03	Sandoz Ag	Novel crystalline form of Prasugrel hydrogensulphate
HU3745U (en)	2009-10-01	2010-03-29	Laszlo Borzan	Disk guide device for target disk launcher or bowler equipments

2001
- 2001-12-20 PL PL363183A patent/PL206138B1/pl unknown
- 2001-12-20 CA CA2432644A patent/CA2432644C/en not_active Expired - Lifetime
- 2001-12-20 CN CNB018227686A patent/CN100341506C/zh not_active Expired - Lifetime
- 2001-12-20 IL IL15645601A patent/IL156456A0/xx active IP Right Grant
- 2001-12-20 NZ NZ526540A patent/NZ526540A/en not_active IP Right Cessation
- 2001-12-20 DE DE60135780T patent/DE60135780D1/de not_active Expired - Lifetime
- 2001-12-20 AT AT01271850T patent/ATE407675T1/de active
- 2001-12-20 CZ CZ20031660A patent/CZ297570B6/cs not_active IP Right Cessation
- 2001-12-20 EP EP01271850A patent/EP1350511B1/en not_active Revoked
- 2001-12-20 MX MXPA03005770A patent/MXPA03005770A/es active IP Right Grant
- 2001-12-20 WO PCT/JP2001/011201 patent/WO2002051412A1/ja not_active Ceased
- 2001-12-20 HU HU0400644A patent/HUP0400644A3/hu not_active Application Discontinuation
- 2001-12-20 PT PT01271850T patent/PT1350511E/pt unknown
- 2001-12-20 RU RU2003118638/15A patent/RU2262933C2/ru active
- 2001-12-20 BR BR0116531-3A patent/BR0116531A/pt not_active Application Discontinuation
- 2001-12-20 KR KR1020037008323A patent/KR100692934B1/ko not_active Expired - Lifetime
- 2001-12-20 ES ES01271850T patent/ES2311498T3/es not_active Expired - Lifetime
- 2001-12-20 DK DK01271850T patent/DK1350511T3/da active
- 2001-12-20 AU AU2002217464A patent/AU2002217464B2/en not_active Expired
- 2001-12-20 SK SK754-2003A patent/SK287972B6/sk not_active IP Right Cessation
- 2001-12-25 TW TW090132160A patent/TWI293249B/zh not_active IP Right Cessation
2003
- 2003-06-16 IL IL156456A patent/IL156456A/en unknown
- 2003-06-20 US US10/600,266 patent/US20040024013A1/en active Granted
- 2003-06-23 ZA ZA200304878A patent/ZA200304878B/en unknown
- 2003-06-24 NO NO20032902A patent/NO20032902L/no unknown
2006
- 2006-09-13 US US11/520,168 patent/US8404703B2/en not_active Expired - Fee Related
2008
- 2008-01-03 US US12/006,546 patent/US8569325B2/en not_active Expired - Fee Related
- 2008-12-02 CY CY20081101387T patent/CY1108626T1/el unknown

Also Published As

Publication number	Publication date
IL156456A (en)	2006-12-10
EP1350511A4 (en)	2004-06-23
US20070010499A1 (en)	2007-01-11
DE60135780D1 (de)	2008-10-23
ATE407675T1 (de)	2008-09-15
NO20032902D0 (no)	2003-06-24
KR100692934B1 (ko)	2007-03-12
HK1056118A1 (en)	2004-02-06
ZA200304878B (en)	2004-08-10
SK7542003A3 (en)	2003-12-02
CA2432644C (en)	2013-07-23
US20080108589A1 (en)	2008-05-08
CA2432644A1 (en)	2002-07-04
CN100341506C (zh)	2007-10-10
MXPA03005770A (es)	2003-09-10
HUP0400644A3 (en)	2009-06-29
US20040024013A1 (en)	2004-02-05
AU2002217464B2 (en)	2004-12-16
RU2262933C2 (ru)	2005-10-27
WO2002051412A1 (en)	2002-07-04
KR20030065558A (ko)	2003-08-06
US8404703B2 (en)	2013-03-26
CY1108626T1 (el)	2014-04-09
EP1350511A1 (en)	2003-10-08
PL363183A1 (en)	2004-11-15
BR0116531A (pt)	2004-02-25
CN1491109A (zh)	2004-04-21
TWI293249B (en)	2008-02-11
US8569325B2 (en)	2013-10-29
EP1350511B1 (en)	2008-09-10
PL206138B1 (pl)	2010-07-30
HUP0400644A2 (hu)	2004-06-28
IL156456A0 (en)	2004-01-04
NO20032902L (no)	2003-06-24
CZ20031660A3 (cs)	2003-12-17
CZ297570B6 (cs)	2007-02-07
PT1350511E (pt)	2008-10-28
ES2311498T3 (es)	2009-02-16
DK1350511T3 (da)	2009-01-05
NZ526540A (en)	2004-11-26

Legal Events

Date

Code

Title

Description

2012-12-03

SPCF

Filing of an spc

Free format text: PRODUCT NAME: PRASUGRELUM; REGISTRATION NO/DATE: EU/1/08/503/001 - EU/1/08/503/014 20090225

Spc suppl protection certif: 5017-2012

Filing date: 20120807

2014-11-04

SPCR

Rejection of an spc

Free format text: PRODUCT NAME: PRASUGRELUM; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225